Search | TVST | ARVO Journals

Showing 1 – 20 of 32

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract June 2024

Inhibition of VEGFA induced HUVEC migration via RO-104, a novel trispecific protein

Yixuan Ma; Alina K Sinha; Li Xu; Peter K Kaiser; Arshad M. Khanani; Jeffrey S Heier; Jessi Prentice; Parth Patel; Ashwin Gupta; Nikhil Gupta; Megana Paidela; Isabel Ray; Ramesh Bhatt; Ramanath Bhandari

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):1942.

ARVO Annual Meeting Abstract June 2024

Assessment of pre-existing anti-drug antibodies (ADAs) in pooled serum against novel trispecific biologic RO-104 analogs

Isabel Ray; Alina K Sinha; Li Xu; Peter M Kaiser; Arshad M. Khanani; Jeffrey S Heier; Jessi Prentice; Parth Patel; Nikhil Gupta; Ashwin Gupta; Megana Paidela; Yixuan Ma; Ramesh Bhatt; Ramanath Bhandari

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):715.

ARVO Annual Meeting Abstract June 2024

Rat Laser CNV Efficacy Studies with the Novel Trispecific Protein RO-104

Alina K Sinha; Li Xu; Peter K Kaiser; Arshad M. Khanani; Jeffrey S Heier; Jessi Prentice; Parth Patel; Nikhil Gupta; Ashwin Gupta; Megana Paidela; Isabel Ray; Yixuan Ma; Ramesh Bhatt; Ramanath Bhandari

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):2163.

ARVO Annual Meeting Abstract June 2024

The EC50 binding characteristics of novel trispecific protein, RO-104

Parth Patel; Li Xu; Peter K Kaiser; Arshad M. Khanani; Jeffrey S Heier; Alina K Sinha; Nikhil Gupta; Ashwin Gupta; Megana Paidela; Isabel Ray; Yixuan Ma; Jessi Prentice; Ramanath Bhandari; Ramesh Bhatt

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):5088.

ARVO Annual Meeting Abstract June 2024

Binding characteristics of a novel trispecific protein RO-104 to aflibercept

Megana Paidela; Li Xu; Peter M Kaiser; Arshad M. Khanani; Jeffrey S Heier; Jessi Prentice; Parth Patel; Nikhil Gupta; Ashwin Gupta; Alina K Sinha; Isabel Ray; Yixuan Ma; Ramesh Bhatt; Ramanath Bhandari

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):1950.

ARVO Annual Meeting Abstract June 2024

Characterization of the Receptor-Ligand Competition of RO-104 IC50 Potencies

Ashwin Gupta; Li Xu; Peter K Kaiser; Arshad M. Khanani; Jeffrey S Heier; Jessi Prentice; Ramesh Bhatt; Parth Patel; Alina K Sinha; Nikhil Gupta; Megana Paidela; Isabel Ray; Yixuan Ma; Ramanath Bhandari

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):264.

ARVO Annual Meeting Abstract June 2024

Pharmacokinetic Analysis of RO-104 in Rabbit Eye Vitreous

Nikhil Gupta; Li Xu; Peter K Kaiser; Arshad M. Khanani; Jeffrey S Heier; Jessi Prentice; Parth Patel; Ashwin Gupta; Alina K Sinha; Megana Paidela; Isabel Ray; Yixuan Ma; Ramesh Bhatt; Ramanath Bhandari

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):263.

ARVO Annual Meeting Abstract June 2024

The Real-World Efficacy and Safety of Faricimab in Neovascular Age-Related Macular Degeneration: The TRUCKEE Study - 2 Year Results

Aamir Abdul Aziz; Hannah Khan; Mark Rami Barakat; Ramanath Bhandari; Emmanuel Chang; Giulia Corradetti; Carl J Danzig; Jordan M Graff; Nikolas JS London; Jared Nielsen; Veeral Sheth; Jeremy Wolfe; Robert William Wong; SriniVas R Sadda; Michael Andrew Singer; Arshad M. Khanani

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):2789.

ARVO Annual Meeting Abstract June 2024

Subretinal delivery of investigational ABBV-RGX-314 for neovascular age-related macular degeneration (nAMD): A phase II pharmacodynamic study

Ramanath Bhandari

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):4903.

ARVO Annual Meeting Abstract June 2024

Visual and Anatomic Outcomes in nAMD Patients with Subretinal Hemorrhage After Treatment with Faricimab in the TRUCKEE Study

Ohidul Mojumder; Aamir Abdul Aziz; Hannah Khan; Ashkan Michael Abbey; Robert L Avery; Himanshu K Banda; Mark Rami Barakat; Ramanath Bhandari; Emmanuel Chang; Sara Haug; Nikolas London; Veeral Sheth; Jeremy Wolfe; Michael Andrew Singer; Carl J Danzig; Arshad M. Khanani

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):5675.

ARVO Annual Meeting Abstract June 2023

The Real-World Efficacy and Safety of Faricimab in Neovascular Age-Related Macular Degeneration: The TRUCKEE Study

Aamir Abdul Aziz; Hannah Khan; Ashkan Michael Abbey; David RP Almeida; Robert L Avery; Himanshu K Banda; Mark Barakat; Ramanath Bhandari; Emmanuel Y Chang; Sara Haug; Nikolas J S London; Veeral Sheth; Jeremy Wolfe; Michael Andrew Singer; Carl J Danzig; Arshad M. Khanani

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):2190.

ARVO Annual Meeting Abstract June 2023

Visual and Anatomic Outcomes in nAMD Patients with Subretinal Hemorrhage After Treatment with Faricimab in the TRUCKEE Study

Hannah Khan; Aamir Abdul Aziz; Ashkan Michael Abbey; David RP Almeida; Robert L Avery; Himanshu K Banda; Mark Barakat; Ramanath Bhandari; Emmanuel Y Chang; Sara Haug; Nikolas J S London; Veeral Sheth; Jeremy Wolfe; Michael Andrew Singer; Carl J Danzig; Arshad M. Khanani

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):2187.

ARVO Annual Meeting Abstract June 2023

The Characterization of the Ang-2 Arm of a Novel Anti-VEGF-A and Ang-2 Bispecific Protein (RO-101) in Comparison to Faricimab-svoa

Megana Paidela; Li Xu; Parth Patel; John Mitchell Kunzeman; Jessi Prentice; Robert Lowenthal; Mark Barakat; Arshad M. Khanani; Peter K Kaiser; Jeffrey L. Olson; Jeffrey S Heier; Ramanath Bhandari

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):739.

ARVO Annual Meeting Abstract June 2023

Binding Characteristics of the VEGF Arm of a Novel Bispecific Protein RO-101 in Comparison to Faricimab-svoa

Parth Patel; Li Xu; Megana Paidela; John Mitchell Kunzeman; Jessi Prentice; Mark Barakat; Robert Lowenthal; Arshad M. Khanani; Peter M Kaiser; Jeffrey S Heier; Jeffrey L. Olson; Ramanath Bhandari

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):738.

ARVO Annual Meeting Abstract June 2022

Assessing Inhibition of HUVEC Migration by a Novel VEGF-A and Angiopoietin-2 Bispecific Protein (RO-634)

John Kunzeman; Jeffrey L Olson; Anthony Jones; Josh Morgenstern; Anne Strong; Steven Droho; Shaun Bevers; Niklaus Mueller; Michael Huvard; Li Xu; Peter K Kaiser; Arshad M. Khanani; Jeffrey S Heier; Nikhil Gupta; Alina Sinha; Ramanath Bhandari

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):1325 – F0159.

ARVO Annual Meeting Abstract June 2022

The Half Maximal Effective Concentration (EC50) of a Novel VEGF-A and Ang-2 Bispecific Protein (RO-634) for Back of the Eye Disease

Alina Sinha; Jeffrey L Olson; Anthony Jones; Josh Morgenstern; Anne Strong; Steven Droho; Shaun Bevers; Niklaus Mueller; Michael Huvard; Li Xu; Peter K Kaiser; Arshad M. Khanani; Jeffrey S Heier; John M Kunzeman; Evan Sembell; Ramanath Bhandari

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):1316 – F0150.

ARVO Annual Meeting Abstract June 2022

Characterizing a Novel Bispecific Platform (Surrobody) for use in Back of the Eye Disease

Ramanath Bhandari; Li Xu; Evan Sembell; Jeffrey L Olson; Peter M Kaiser; Arshad M. Khanani; Jeffrey S Heier; Alina Sinha; John M Kunzeman; Nikhil Gupta; Ramesh Bhatt

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):302 – F0105.

ARVO Annual Meeting Abstract June 2022

Determining the Ocular Biocompatibility of a Novel VEGF-A and Ang-2 Bispecific Protein (RO-634) Through Histological Analysis

Evan Sembell; Jeffrey L Olson; Anthony Jones; Josh Morgenstern; Anne Strong; Steven Droho; Niklaus Mueller; Michael Huvard; Shaun Bevers; Li Xu; Peter K Kaiser; Arshad M. Khanani; Jeffrey S Heier; Nikhil Gupta; John M Kunzeman; Ramanath Bhandari

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):305 – F0108.

ARVO Annual Meeting Abstract June 2022

Preclinical Animal Model for Functional Biocompatibility of a Novel VEGF and Ang-2 Bispecific Protein (RO-634) Using ERG Analysis

Nikhil Gupta; Jeffrey L Olson; Anthony Jones; Josh Morgenstern; Anne Strong; Steven Droho; Shaun Bevers; Niklaus Mueller; Michael Huvard; Li Xu; Peter K Kaiser; Arshad M. Khanani; Jeffrey S Heier; Alina Sinha; Evan Sembell; Ramanath Bhandari

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):286 – F0089.

ARVO Annual Meeting Abstract June 2022

RO-634 half-life as compared to published data on Aflibercept, Faricimab, Ranibizumab, and Bevacizumab.

Zafar Gill; Jeffrey L Olson; Josh Morgenstern; Anthony Jones; Anne Strong; Steven Droho; Shaun Bevers; Niklaus Mueller; Nihaal Mehta; Michael Huvard; Peter K Kaiser; Ramanath Bhandari

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):308 – F0111.

1 2

Next 20 Results »

NARROW

Content Type

Journal

Article Type

Topics

Tags

Specify Date Range

Inhibition of VEGFA induced HUVEC migration via RO-104, a novel trispecific protein

Assessment of pre-existing anti-drug antibodies (ADAs) in pooled serum against novel trispecific biologic RO-104 analogs

Rat Laser CNV Efficacy Studies with the Novel Trispecific Protein RO-104

The EC50 binding characteristics of novel trispecific protein, RO-104

Binding characteristics of a novel trispecific protein RO-104 to aflibercept

Characterization of the Receptor-Ligand Competition of RO-104 IC50 Potencies

Pharmacokinetic Analysis of RO-104 in Rabbit Eye Vitreous

The Real-World Efficacy and Safety of Faricimab in Neovascular Age-Related Macular Degeneration: The TRUCKEE Study - 2 Year Results

Subretinal delivery of investigational ABBV-RGX-314 for neovascular age-related macular degeneration (nAMD): A phase II pharmacodynamic study

Visual and Anatomic Outcomes in nAMD Patients with Subretinal Hemorrhage After Treatment with Faricimab in the TRUCKEE Study

The Real-World Efficacy and Safety of Faricimab in Neovascular Age-Related Macular Degeneration: The TRUCKEE Study

Visual and Anatomic Outcomes in nAMD Patients with Subretinal Hemorrhage After Treatment with Faricimab in the TRUCKEE Study

The Characterization of the Ang-2 Arm of a Novel Anti-VEGF-A and Ang-2 Bispecific Protein (RO-101) in Comparison to Faricimab-svoa

Binding Characteristics of the VEGF Arm of a Novel Bispecific Protein RO-101 in Comparison to Faricimab-svoa

Assessing Inhibition of HUVEC Migration by a Novel VEGF-A and Angiopoietin-2 Bispecific Protein (RO-634)

The Half Maximal Effective Concentration (EC50) of a Novel VEGF-A and Ang-2 Bispecific Protein (RO-634) for Back of the Eye Disease

Characterizing a Novel Bispecific Platform (Surrobody) for use in Back of the Eye Disease

Determining the Ocular Biocompatibility of a Novel VEGF-A and Ang-2 Bispecific Protein (RO-634) Through Histological Analysis

Preclinical Animal Model for Functional Biocompatibility of a Novel VEGF and Ang-2 Bispecific Protein (RO-634) Using ERG Analysis

RO-634 half-life as compared to published data on Aflibercept, Faricimab, Ranibizumab, and Bevacizumab.

To View More...

You must be signed into an individual account to use this feature.